Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 9:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 5,477 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor
Interventions
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • New York, New York • Houston, Texas
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Cancers
Interventions
LY2606368
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose F 18
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
Interventions
ART0380
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 16 more
Conditions
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
Interventions
FMC-376
Drug
Lead sponsor
Frontier Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 11 more
Conditions
Advanced Solid Tumors
Interventions
MEDI1873
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
475
States / cities
Antioch, California • Berkeley, California • Burlingame, California + 328 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Tumors
Interventions
Liposome Encapsulated Mitoxantrone (LEM)
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Detroit, Michigan + 1 more
Conditions
Advanced Cancer, Solid Tumors
Interventions
Sodium Stibogluconate, Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Conditions
Cancer
Interventions
Ascorbic Acid
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Zion, Illinois
Conditions
Cancer, Lymphomas
Interventions
NPI-0052
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Houston, Texas
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Conditions
Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Hodgkin Lymphoma, Bone Tumor, Soft Tissue Sarcoma
Interventions
Proton Therapy (Adaptive)
Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS, Solid Tumor, B-Cell Lymphoma
Interventions
ASP3026
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Orange, California • Sacramento, California • Chicago, Illinois + 3 more
Conditions
Solid Tumor
Interventions
AT03-65
Drug
Lead sponsor
Axcynsis Therapeutics Pte Ltd
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Denver, Colorado • New Haven, Connecticut • Portland, Oregon + 1 more
Conditions
Pediatric Cancers, Hematologic Malignancies, Solid Tumors
Interventions
anti-CD19 CAR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neoplasm, Lymphoma
Interventions
LMP400
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Kidney Cancer, Lung Cancer
Interventions
interleukin-4 PE38KDEL cytotoxin
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Solid Tumors, Metastatic Solid Tumors
Interventions
DS3610a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Ovarian Cancer, Recurrent Solid Tumors
Interventions
ZEN003694, Niraparib
Drug
Lead sponsor
Haider Mahdi
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania